Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)
This study has been completed.
Sponsor:
Novagali Pharma
Information provided by:
Novagali Pharma
ClinicalTrials.gov Identifier:
NCT00328653
First received: May 19, 2006
Last updated: August 20, 2008
Last verified: August 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this study is:
- To assess the efficacy of Nova22007, a cyclosporine A (CsA), 0.05% and 0.1% versus vehicle in patients with vernal keratoconjunctivitis (VKC) after a 4-week treatment period.
The secondary objectives of this study are:
- To compare the safety and ocular tolerance of Nova22007 0.05% and 0.1%;
- To assess the long term safety and ocular tolerance of Nova22007 0.05% and 0.1%; and
- To assess the decrease in frequency of concomitant artificial tears use.
| Condition | Intervention | Phase |
|---|---|---|
|
Conjunctivitis, Vernal |
Drug: cyclosporine |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind |
| Official Title: | Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC |
Resource links provided by NLM:
Genetics Home Reference related topics:
keratitis-ichthyosis-deafness syndrome
MedlinePlus related topics:
Pinkeye
Drug Information available for:
Cyclosporine
U.S. FDA Resources
Further study details as provided by Novagali Pharma:
Eligibility| Ages Eligible for Study: | 4 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
At least the two following signs, in at least one eye* (the same eye should fulfill both criteria):
- Presence of giant papillae with a diameter ≥ 1 mm on the upper tarsal conjunctiva AND
- Superficial keratitis
- At least two of the following ocular symptoms with a score > 2 in at least one eye*: burning/stinging, tearing, itching, pain, sticky eyelids, foreign body sensation, mucus discharge, and photophobia.
- Hyperemia score equal to or greater than 2.
Exclusion Criteria:
- Concomitant corneal ulcer of infectious origin.
- Active ocular herpes
- Disease that could possibly interfere with the interpretation of the study results: active uveitis (defined by Tyndall score > 0), previous history of ocular hypertension or glaucoma, or condition incompatible with the frequent assessments needed by the study.
- Active herpes.
- History of malignancy or a recurrence in the last 5 years.
- Abnormality of nasolacrimal drainage apparatus.
- Concomitant disease not stabilized within 1 month before Screening Visit (e.g. diabetes with glycemia out of range, trouble with thyroid secretions, etc.) or judged by the investigator to be incompatible with the study (e.g. current systemic infections), or condition incompatible with the frequent assessments needed by the study.
- Known hypersensitivity to one of the components of the investigational medicinal products (IMP) or test products.
- Severe systemic allergy requiring systemic treatment at study entry.
- Female of childbearing potential.
- History of drug or alcohol addiction (> 50g/day, 5 glasses alcohol/day).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00328653
Locations
| France | |
| Groupe Hospitalier Bichat-Claude Bernard | |
| Paris, France, 75018 | |
Sponsors and Collaborators
Novagali Pharma
Investigators
| Principal Investigator: | David BenEzra, Pf | Haddassah University Hospital |
| Study Director: | Christophe Baudoin, Pf. | Hôpital des XV-XX 28 rue de Charenton 75012 Paris |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00328653 History of Changes |
| Other Study ID Numbers: | NOVATIVE - NVG05L101 |
| Study First Received: | May 19, 2006 |
| Last Updated: | August 20, 2008 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Italy: The Italian Medicines Agency Spain: Spanish Agency of Medicines Turkey: Ministry of Health Israel: Israeli Health Ministry Pharmaceutical Administration Morocco: Ministry of Public Health |
Keywords provided by Novagali Pharma:
|
vernal keratoconjunctivitis (VKC), eye, allergy, cyclosporin |
Additional relevant MeSH terms:
|
Conjunctivitis Conjunctivitis, Allergic Keratoconjunctivitis Conjunctival Diseases Eye Diseases Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Keratitis Corneal Diseases Cyclosporins Cyclosporine |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antifungal Agents Anti-Infective Agents Therapeutic Uses Dermatologic Agents Antirheumatic Agents |
ClinicalTrials.gov processed this record on May 19, 2013